Header Logo

Connection

Tina Pesaran to High-Throughput Nucleotide Sequencing

This is a "connection" page, showing publications Tina Pesaran has written about High-Throughput Nucleotide Sequencing.
  1. DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes. Genet Med. 2019 03; 21(3):683-693.
    View in: PubMed
    Score: 0.148
  2. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients. Cancer Genet. 2019 06; 235-236:21-27.
    View in: PubMed
    Score: 0.039
  3. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. Hum Mutat. 2018 11; 39(11):1553-1568.
    View in: PubMed
    Score: 0.038
  4. Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel. Hum Mutat. 2018 11; 39(11):1581-1592.
    View in: PubMed
    Score: 0.038
  5. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat. 2018 11; 39(11):1517-1524.
    View in: PubMed
    Score: 0.037
  6. Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar. Genet Med. 2017 10; 19(10):1096-1104.
    View in: PubMed
    Score: 0.034
  7. Processed Pseudogene Confounding Deletion/Duplication Assays for SMAD4. J Mol Diagn. 2015 Sep; 17(5):576-82.
    View in: PubMed
    Score: 0.030
  8. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014 Nov; 16(11):830-7.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.